Amylyx Pharmaceuticals Inc (AMLX) - Total Assets
Based on the latest financial reports, Amylyx Pharmaceuticals Inc (AMLX) holds total assets worth $332.64 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Amylyx Pharmaceuticals Inc for net asset value and shareholders' equity analysis.
Amylyx Pharmaceuticals Inc - Total Assets Trend (2019–2025)
This chart illustrates how Amylyx Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Amylyx Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Amylyx Pharmaceuticals Inc's total assets of $332.64 Million consist of 97.3% current assets and 2.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 68.1% |
| Accounts Receivable | $88.00K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Amylyx Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Amylyx Pharmaceuticals Inc (AMLX) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amylyx Pharmaceuticals Inc's current assets represent 97.3% of total assets in 2025, a decrease from 99.4% in 2019.
- Cash Position: Cash and equivalents constituted 68.1% of total assets in 2025, down from 95.2% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Amylyx Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Amylyx Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Daihan Pharmaceutical Co.Ltd
KQ:023910
|
Korea | ₩344.02 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs525.46 Billion |
|
China Resources Sanjiu Medical & Pharmaceutical Co Ltd
SHE:000999
|
China | CN¥56.56 Billion |
|
Ningbo Menovo Pharm Co Ltd
SHG:603538
|
China | CN¥4.75 Billion |
|
Zhejiang Xianju Pharmaceutical Co Ltd
SHE:002332
|
China | CN¥7.26 Billion |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
China | CN¥2.26 Billion |
|
Zhejiang Cheng Yi Pharmaceutical Co Ltd
SHG:603811
|
China | CN¥1.69 Billion |
|
Hainan Honz Pharmaceutical Co
SHE:300086
|
China | CN¥1.88 Billion |
Amylyx Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.27 | 6.67 | 1.86 |
| Quick Ratio | 14.27 | 6.67 | 1.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $300.98 Million | $161.03 Million | $6.31 Million |
Amylyx Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Amylyx Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.41 |
| Latest Market Cap to Assets Ratio | 5.32 |
| Asset Growth Rate (YoY) | 71.8% |
| Total Assets | $332.64 Million |
| Market Capitalization | $1.77 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Amylyx Pharmaceuticals Inc's assets at a significant premium (5.32x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Amylyx Pharmaceuticals Inc's assets grew by 71.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Amylyx Pharmaceuticals Inc (2019–2025)
The table below shows the annual total assets of Amylyx Pharmaceuticals Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $332.64 Million | +71.79% |
| 2024-12-31 | $193.63 Million | -62.58% |
| 2023-12-31 | $517.45 Million | +32.19% |
| 2022-12-31 | $391.45 Million | +270.64% |
| 2021-12-31 | $105.61 Million | +648.82% |
| 2020-12-31 | $14.10 Million | +338.01% |
| 2019-12-31 | $3.22 Million | -- |
About Amylyx Pharmaceuticals Inc
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and… Read more